The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
The data highlights its RSV vaccine cuts hospitalizations in older adults
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Subscribe To Our Newsletter & Stay Updated
